Literature DB >> 32623496

Ante-natal counseling in phacomatoses.

Dana Brabbing-Goldstein1,2,3, Shay Ben-Shachar4,5.   

Abstract

OBJECTIVES: Phacomatoses are a group of neuro-oculo-cutaneous syndromes/ neurocutaneous disorders, involving structures arising from the embryonic ectoderm. Most of phacomatoses including the most common ones:, neurofibromatosis type I and type II (NF1, NF2) and tuberosclerosis complex (TSC), are autosomal dominant genetic disorders with full penetrance and variable expression. As no effective treatment exists, the only way to prevent the disease, is by prenatal genetic diagnosis (either chorionic villus sampling-CVS or amniocentesis-AC) and termination of pregnancy or performing preimplantation genetic testing (PGT). As the risk for an affected offspring is 50% in every pregnancy of an affected parent, prenatal, and preimplantation testing are of great importance. However, those procedures are associated with technical and ethical concerns. This chapter shortly reviews the common phacomatoses emphasizes their genetics and inheritance. We will review the common methods for prenatal and preimplantation diagnoses and discuss its use in common phacomatoses.
CONCLUSION: Phacomatoses are common autosomal dominant genetic conditions with variable expression. Ante-natal genetic diagnosis is an appropriate approach for family planning in individuals affected by phacomatosis or parents of an affected child.

Entities:  

Keywords:  Amniocentesis; Chorionic villi sampling; Germline gene editing; Neurofibromatosis type 1; Neurofibromatosis type 2; Phacomatoses; Preimplantation genetic testing; Prenatal genetic counseling; Prenatal genetic diagnosis; Tuberosclerosis complex

Mesh:

Year:  2020        PMID: 32623496     DOI: 10.1007/s00381-020-04776-3

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  59 in total

1.  Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.

Authors:  Matthew D Shirley; Hao Tang; Carol J Gallione; Joseph D Baugher; Laurence P Frelin; Bernard Cohen; Paula E North; Douglas A Marchuk; Anne M Comi; Jonathan Pevsner
Journal:  N Engl J Med       Date:  2013-05-08       Impact factor: 91.245

Review 2.  NF1 gene and neurofibromatosis 1.

Authors:  S A Rasmussen; J M Friedman
Journal:  Am J Epidemiol       Date:  2000-01-01       Impact factor: 4.897

3.  Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients.

Authors:  K Wimmer; S Yao; K Claes; H Kehrer-Sawatzki; S Tinschert; T De Raedt; E Legius; T Callens; H Beiglböck; O Maertens; L Messiaen
Journal:  Genes Chromosomes Cancer       Date:  2006-03       Impact factor: 5.006

4.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

Authors:  Shelley L Hyman; E Arthur Shores; Kathryn N North
Journal:  Dev Med Child Neurol       Date:  2006-12       Impact factor: 5.449

5.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

Authors:  L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

6.  Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.

Authors:  Irene Bottillo; Terje Ahlquist; Helge Brekke; Stine A Danielsen; Eva van den Berg; Fredrik Mertens; Ragnhild A Lothe; Bruno Dallapiccola
Journal:  J Pathol       Date:  2009-04       Impact factor: 7.996

7.  Germline and somatic NF1 gene mutations in plexiform neurofibromas.

Authors:  Meena Upadhyaya; Gill Spurlock; Bisma Monem; Nick Thomas; Reinhard E Friedrich; Lan Kluwe; Victor Mautner
Journal:  Hum Mutat       Date:  2008-08       Impact factor: 4.878

Review 8.  Advances in Molecular Diagnosis of Neurofibromatosis Type 1.

Authors:  Ben Shofty; Shlomi Constantini; Shay Ben-Shachar
Journal:  Semin Pediatr Neurol       Date:  2015-10-28       Impact factor: 1.636

Review 9.  Neurofibromatosis type 1 revisited.

Authors:  Virginia C Williams; John Lucas; Michael A Babcock; David H Gutmann; Bruce Korf; Bernard L Maria
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

10.  Prevalence of neurofibromatosis type 1 in the Finnish population.

Authors:  Roope A Kallionpää; Elina Uusitalo; Jussi Leppävirta; Minna Pöyhönen; Sirkku Peltonen; Juha Peltonen
Journal:  Genet Med       Date:  2017-12-07       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.